UNCY · Insider Trading
Unicycive Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by UNCY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-28 | Sara Kenkare-Mitra | Director | A | +47,941 deriv. | — |
| 2026-07-28 | Sandeep Laumas | Director | A | +47,941 deriv. | — |
| 2026-06-15 | Douglas Jermasek | EVP, Corporate Strategy | A | +169,500 deriv. | — |
| 2026-06-15 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +169,500 deriv. | — |
| 2026-06-15 | Shalabh K. Gupta | CEO | A | +762,200 deriv. | — |
| 2026-06-15 | John Townsend | CFO | A | +169,500 deriv. | — |
| 2026-06-15 | Sara Kenkare-Mitra | Director | A | +126,300 deriv. | — |
| 2026-06-15 | Sandeep Laumas | Director | A | +126,300 deriv. | — |
| 2026-05-21 | Shalabh K. Gupta | CEO | A | +762,200 deriv. | — |
| 2026-05-21 | Sara Kenkare-Mitra | Director | A | +126,300 deriv. | — |
| 2026-05-20 | Douglas Jermasek | EVP, Corporate Strategy | A | +169,500 deriv. | — |
| 2026-05-20 | John Townsend | CFO | A | +169,500 deriv. | — |
| 2026-05-20 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +169,500 deriv. | — |
| 2026-05-18 | Sandeep Laumas | Director | A | +126,300 deriv. | — |
| 2025-08-26 | Gaurav Aggarwal | Director | C | +652,900 | — |
| 2025-07-30 | Sara Kenkare-Mitra | Director | A | +21,200 deriv. | — |
| 2025-07-30 | Gaurav Aggarwal | Director | A | +21,200 deriv. | — |
| 2025-07-30 | John Townsend | Chief Financial Officer | A | +10,000 deriv. | — |
| 2025-07-30 | Shalabh K. Gupta | CEO | A | +325,000 deriv. | — |
| 2025-07-30 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +90,000 deriv. | — |
| 2025-07-30 | Sandeep Laumas | Director | A | +21,200 deriv. | — |
| 2025-07-30 | Douglas Jermasek | EVP of Corporate Strategy | A | +10,000 deriv. | — |
| 2025-02-19 | Gaurav Aggarwal | Director | C | +1,400,000 | — |
| 2024-10-10 | Gaurav Aggarwal | Director | C | +5,500,000 | — |
| 2024-08-14 | Shalabh K. Gupta | CEO | A | +232,868 deriv. | — |
| 2024-08-14 | John Townsend | Chief Financial Officer | A | +40,256 deriv. | — |
| 2024-08-14 | Douglas Jermasek | EVP of Corporate Strategy | A | +81,750 deriv. | — |
| 2024-08-14 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +81,750 deriv. | — |
| 2024-04-17 | Douglas Jermasek | EVP of Corporate Strategy | A | +463,250 deriv. | — |
| 2024-04-17 | John Townsend | Chief Financial Officer | A | +228,119 deriv. | — |
| 2024-04-17 | Shalabh K. Gupta | CEO | A | +1,319,583 deriv. | — |
| 2024-04-17 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +463,250 deriv. | — |
| 2023-09-07 | John L Ryan | Director | A | +112,147 deriv. | — |
| 2023-09-07 | Sandeep Laumas | Director | A | +189,236 deriv. | — |
| 2023-09-07 | Sara Kenkare-Mitra | Director | A | +180,000 deriv. | — |
| 2023-09-07 | Gaurav Aggarwal | Director | A | +180,000 deriv. | — |
| 2023-08-30 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +1,355,000 deriv. | — |
| 2023-08-30 | John Townsend | Chief Financial Officer | A | +570,329 deriv. | — |
| 2023-08-30 | Douglas Jermasek | EVP of Corporate Strategy | A | +1,355,000 deriv. | — |
| 2023-08-30 | Shalabh K. Gupta | CEO | A | +4,684,775 deriv. | — |
| 2023-07-13 | Gaurav Aggarwal | Director | C | +3,470,152 | — |
| 2023-07-13 | Shalabh K. Gupta | CEO | M | +104,612 | — |
| 2023-07-13 | Douglas Jermasek | EVP of Corporate Strategy | M | +104,612 | — |
| 2023-07-13 | Pramod Gupta | EVP, Pharmaceuticals and BD | M | +41,845 | — |
| 2023-04-18 | Brigitte Schiller | Director | — | — | — |
| 2023-03-09 | Gaurav Aggarwal | Director | A | +8,077 deriv. | — |
| 2023-03-09 | Pramod Gupta | EVP, Pharmaceuticals and BD | A | +20 deriv. | — |
| 2023-03-09 | Shalabh K. Gupta | CEO | A | +50 deriv. | — |
| 2023-03-09 | Douglas Jermasek | EVP of Corporate Strategy | A | +50 deriv. | — |
| 2022-11-23 | Douglas Jermasek | EVP of Corporate Strategy | A | +55,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gaurav Aggarwal | Director | 1,789,915 | $6.41M |
| Shalabh K. Gupta | CEO | 252,745 | $904.83K |
| Douglas Jermasek | EVP, Corporate Strategy | 17,501 | $62.65K |
| Pramod Gupta | EVP, Pharmaceuticals and BD | 4,184 | $14.98K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the UNCY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.